At a glance
- Originator Genta
- Class Antipsoriatics
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 28 Aug 2001 Discontinued-II for Psoriasis in France (Topical)
- 24 Nov 1998 No-Development-Reported for Psoriasis in France (Topical)